Home
Storia in 2 fonti
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.
- ·
ft.com
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
- ·
cnbc.com
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of $7.8 billion.